GSTM1 and non-autoimmune hemolytic anemia: As such, PROs generally track the clinical data, which indicate that haemolytic anaemia recurred in most patients once treatment was discontinued, with mean levels of haemolytic markers and Hb approaching pre-treatment values upon cessation of sutimlimab.13